HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kang, E. S. Articles by Lee, H. C. Search for Related Content PubMed PubMed Citation Articles by Kang, E. S. Articles by Lee, H. C. Social Bookmarking                What's this?

The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
² Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea
³ Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
⁴ Department of Endocrinology and Metabolism, Ajou University College of Medicine, Suwon, Korea

Address correspondence and reprint requests to Hyun Chul Lee, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong Seodaemun-Gu, Seoul, 120-752, Korea. E-mail: endohclee{at}yumc.yonsei.ac.kr

OBJECTIVE—The aim of this study was to examine the effects of perilipin gene (PLIN) polymorphisms on weight gain with rosiglitazone treatment in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—A total of 160 type 2 diabetic patients were treated with rosiglitazone (4 mg/day) for 12 weeks in addition to their previous medications, which were unchanged. Four single nucleotide polymorphisms (SNPs) at the PLIN locus were genotyped: PLIN 6209T>C, PLIN 11482G>A, PLIN 13041A>G, and PLIN 14995A>T.

RESULTS—Although fasting plasma glucose and HbA_1c levels decreased; mean body weight increased significantly after rosiglitazone treatment. Among the four SNPs tested, only the PLIN 11482G>A polymorphism was associated with weight gain from rosiglitazone treatment. In addition, there was a significant difference in the increase in the body weight among the genotypes. Patients with the 11482A/A genotype showed less increase in body weight than those with other genotypes.

CONCLUSIONS—These data suggest that genetic variations in the perilipin gene can affect weight gain associated with rosiglitazone treatment in patients with type 2 diabetes.

Abbreviations: FPG, fasting plasma glucose • HOMA-IR, homeostasis model assessment of insulin resistance • HSL, hormone-sensitive lipase • PPAR, peroxisome proliferator–activated receptor, SNP, single nucleotide polymorphism • TZD, thiazolidinedione

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Perez-Martinez, N. Yiannakouris, J. Lopez-Miranda, D. Arnett, M. Tsai, E. Galan, R. Straka, J. Delgado-Lista, M. Province, J. Ruano, et al. Postprandial triacylglycerol metabolism is modified by the presence of genetic variation at the perilipin (PLIN) locus in 2 white populations Am. J. Clinical Nutrition, March 1, 2008; 87(3): 744 - 752. [Abstract] [Full Text] [PDF]